Aprea Therapeutics Inc. Common stock (APRE)
Stock · NASDAQ · Health Care
$0.584as of 10/16/2026
Price chart
Active signals
APRE Signal Track Record
How signals performed across all stocks →What APRE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -7.1% | 42% | September 29, 2026 |
| Bollinger Band Breakdown | 19 | -2.5% | 37% | October 5, 2026 |
| Bollinger Band Breakout | 17 | -2.7% | 47% | August 24, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -16.0% | 25% | September 2, 2026 |
| Any 20-session window (baseline) | -5.4% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- www.aprea.com/
Fundamentals
- 1-day range
- $0.5758$0.6379
- Market cap
- $7.83M
- P/E (trailing)
- —
- P/E (forward)
- -1.78
- EPS (trailing)
- $-1.08
- Dividend yield
- —
- Beta
- -1.26
- Avg. volume
- 277.5K
Forecasts
3 analyst ratings
Aprea Therapeutics Inc. Common stock Competitors
Chosen by industry and closest market cap.
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
- CNSPCNS Pharmaceuticals Inc. Common Stock$4.85▼ 6.30%Market cap $7.65MP/E —$1.9$10.54
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- ENSCEnsysce Biosciences Inc. Common Stock$0.518▼ 13.38%Market cap $8.06MP/E —$0.23$2.75
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $4.85 | ▼ 6.30% | $1.9$10.54 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| ENSC Ensysce Biosciences Inc. Common Stock | $8.06M | — | $0.518 | ▼ 13.38% | $0.23$2.75 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR SymposiumYahoo · 9/22/2026
- Aprea Therapeutics Announces Abstract Featuring Updated Interim Results From The Ongoing Phase 1 ACESOT-1051 Study Of Its WEE1 Inhibitor APR-1051 In Patients With Advanced Solid Tumors Has Been Accepted For Oral Presentation At The Symposium On Molecular Targets And Cancer TherapeuticsBenzinga · 9/22/2026
Insider Activity
Insider Actions →- John B. Henneman III · June 16, 2026 · Grant3.1K
- Jean-Pierre Bizzari · June 16, 2026 · Grant12.6K
- Jean-Pierre Bizzari · June 16, 2026 · Grant3.1K
- John B. Henneman III · June 16, 2026 · Grant12.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.21M
- Total value held
- $1.68M
- Institutional holders
- 21
- Unknown1.02M
- Unknown350.0K
- Unknown270.0K
- Unknown205.8K
- Unknown119.1K
- Unknown60.3K
- Unknown39.8K
- Unknown25.1K
- Unknown22.3K
- Unknown21.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations
Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.